Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoVax HSV vaccine
- Development stage
- Preclinical
- Lead developer
- BlueWillow Biologics
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
**NanoVax HSV vaccine** is a preclinical intranasal protein-subunit vaccine candidate developed by NanoBio and subsequently BlueWillow Biologics for prophylactic and therapeutic management of genital herpes. The studied formulation contains herpes simplex virus type 2 surface glycoproteins gB2 and gD2 formulated with BlueWillow's NanoVax oil-in-water nanoemulsion adjuvant, also termed NE01 or W805EC. Intranasal delivery is intended to induce mucosal, systemic, and cellular antiviral immune responses. In guinea-pig genital-herpes models, the candidate reduced acute and recurrent disease and viral shedding; BlueWillow reported prevention of infection in 92 percent of vaccinated animals in a prophylactic study and greater than 50 percent reductions in recurrent lesions and shedding in previously infected animals. ([bluewillow.com](https://bluewillow.com/bluewillow-biologics-awarded-patent-for-intranasal-genital-herpes-vaccine/))
- Other names
- gB2/gD2-NE01IN NE01-gD2/gB2NE01-gD2/gB2
02
Targets
gD (HSV-2 glycoprotein D)
Beyond the preview
Go deeper on NanoVax HSV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoVax HSV vaccine.